TD Cowen maintains argenx stock Buy rating, $761 target

Published 17/04/2025, 11:22
TD Cowen maintains argenx stock Buy rating, $761 target

On Thursday, TD Cowen reiterated its Buy rating on argenx SE (NASDAQ:ARGX) with a steady price target of $761.00. The firm’s confidence in the stock is bolstered by a recent survey indicating strong market adoption of argenx’s Vyvgart for treating chronic inflammatory demyelinating polyneuropathy (CIDP) and generalized myasthenia gravis (gMG). The company, currently valued at $36.16 billion, has demonstrated impressive revenue growth of 77% over the last twelve months, according to InvestingPro data.

The survey conducted by TD Cowen revealed that Vyvgart has experienced robust uptake in the treatment of CIDP/gMG, outpacing competitors such as AstraZeneca (NASDAQ:AZN)’s Soliris/Ultomiris and UCB’s Rystiggo/Zilbrysq in the gMG market. Despite the steady growth in gMG adoption, Vyvgart’s rapid acceptance in the CIDP sector is expected to contribute to higher than anticipated earnings for argenx in the first quarter. The company’s strong market performance is reflected in its 60% return over the past year, with a healthy current ratio of 7.29.

TD Cowen’s analysis suggests that argenx’s financial performance is likely to exceed Q1 estimates due to the strong performance of Vyvgart. The firm also notes that argenx is shielded from tariff pressures because of its manufacturing presence in the United States, which adds to the company’s resilience and appeal as an investment. With earnings per share of $13.92 and an overall financial health score rated as "GREAT" by InvestingPro, the company shows strong fundamentals despite trading at a P/E ratio of 42.58.

Argenx ’s commitment to innovation and its robust product pipeline have positioned it as a top pick for TD Cowen. The company’s focus on developing treatments for severe autoimmune diseases and cancer has shown promising results, particularly with the success of Vyvgart in CIDP/gMG treatment.

Investors are keeping a close eye on argenx as the company continues to deliver on its growth strategy and capitalize on the strong market presence of its key product, Vyvgart, in the autoimmune disease treatment space.

In other recent news, Argenx SE received FDA approval for its Vyvgart Hytrulo pre-filled syringe, a significant development for treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). This approval allows patients to self-administer the treatment without healthcare provider monitoring, potentially simplifying the process and enhancing patient access. Analysts from Stifel, H.C. Wainwright, and Guggenheim have maintained their Buy ratings on Argenx, with target prices ranging from $720 to $1,100, reflecting confidence in the company’s market position and growth potential. Bernstein analysts upgraded Argenx from Underperform to Outperform, raising their price target to EUR755, citing improved earnings projections and strong R&D productivity. TD Cowen also reiterated its Buy rating, emphasizing Argenx’s growth prospects and profitability potential by 2025, driven by the successful launch of Vyvgart and anticipated future approvals. The firm’s analysts are optimistic about Argenx’s pipeline, including new indications and potential market expansions. Overall, these recent developments and analyst endorsements indicate a positive outlook for Argenx in the biotechnology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.